APHC Inhibitors

D-erythro-MAPP acts as an acid halide, characterized by its unique reactivity with nucleophiles, leading to the formation of stable intermediates. Its molecular structure allows for selective acylation reactions, which can influence reaction kinetics and product distribution. The compound exhibits distinct solubility properties, enhancing its interaction with various substrates. Additionally, D-erythro-MAPP's ability to form transient complexes with catalysts underscores its role in facilitating diverse synthetic pathways.

Ceranib-2 is an acid ceramidase inhibitor which could inhibit APHC by preventing the hydrolysis of ceramides into sphingosine, thus reducing the sphingosine pool that is necessary for APHC's downstream signaling pathways.

This mycotoxin is a ceramide synthase inhibitor that can lower ceramide levels, potentially reducing the substrate for APHC and thereby inhibiting its function.

Carmofur is a chemotherapy agent that also inhibits acid ceramidase, thus it can functionally inhibit APHC by reducing the breakdown of ceramides and affecting its lipid metabolism pathways.

PDMP is a glucosylceramide synthase inhibitor, which could reduce the glycosphingolipid levels and therefore decrease the availability of APHC substrates, leading to functional inhibition.

SKI-II is another sphingosine kinase inhibitor that can decrease sphingosine-1-phosphate levels, potentially functionally inhibiting APHC by disturbing the sphingolipid signaling pathways.

Safingol is a sphingosine kinase inhibitor that can impede the production of sphingosine-1-phosphate. This can inhibit APHC by causing an imbalance in the sphingolipid rheostat that APHC is involved in regulating.

Myriocin is a serine palmitoyltransferase inhibitor that can lower sphingolipid biosynthesis, potentially inhibiting APHC by cutting down on the pool of sphingolipids that APHC may regulate or interact with.